Drug Profile


Alternative Names: Anti-mimotope antiserum-F9; BCD-F9; Monoclonal antibody BCD-F9

Latest Information Update: 15 Apr 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biophage Pharma; Supratek Pharma; University of Quebec
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 15 Apr 2004 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 11 Feb 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 25 Oct 2000 Preclinical development for Cancer in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top